Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 25, 2017
Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
Transgene (TNG.PA) (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, announces that new and encouraging preclinical data on its next generation ...
July 25, 2017
Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare, Inc.
REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
July 25, 2017
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEWARK, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
July 25, 2017
BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 25, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
July 25, 2017
Gemphire Enters Into $15 Million Term Loan Agreement With Silicon Valley Bank
LIVONIA, Mich., July 25, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced that it has entered into a loan and security agreement with ...
July 25, 2017
Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections
SOUTH SAN FRANCISCO, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative ...
July 25, 2017
Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”
NEWTOWN, Pa., July 25, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small ...
July 24, 2017
VALNEVA Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15
Lyon (France), July 24, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, ...
July 24, 2017
Reata’s Bardoxolone Methyl Demonstrated Improved Kidney Function in Patients With Alport Syndrome in Ongoing Phase 2 Portion of Phase 2/3 Cardinal Study
IRVING, Texas, July 24, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals Inc. (RETA) (“Reata” or “the Company”) today reported initial data from the ongoing open-label Phase ...
July 24, 2017
Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
PALO ALTO, Calif., July 24, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced completion of ...
July 24, 2017
DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM
VANCOUVER, British Columbia and MENLO PARK, Calif., July 24, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer ...
July 24, 2017
Minerva Neurosciences Announces Departure of Directors
WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
July 21, 2017
Aeglea BioTherapeutics Announces Leadership Change
AUSTIN, Texas, July 20, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...
July 21, 2017
TherapeuticsMD to Host Second Quarter Financial Results Conference Call and Webcast on August 3
BOCA RATON, Fla.-- (BUSINESS WIRE) -- TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women’s healthcare company, today announced that it will host a conference call and live ...
July 21, 2017
Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results
MORRISTOWN, N.J., July 20, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced certain preliminary ...
July 21, 2017
Pernix Commences Refinancing Transactions to Fortify Balance Sheet
MORRISTOWN, N.J., July 20, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today commenced a series ...
July 21, 2017
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 21, 2017 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for ...
July 20, 2017
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
Basel, Switzerland, July 20, 2017 - Basilea Pharmaceutica Ltd. (BSLN.SW) reported today that its license agreement with Pfizer Inc. (PFE) for Basilea`s antifungal Cresemba (isavuconazole), ...
July 20, 2017
Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
REHOVOT, Israel, July 20, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the ...
July 20, 2017
BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
ALAMEDA, Calif.--(BUSINESS WIRE) -- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release ...
Page 145 of 158